Ladenburg Thalmann Expands Biotechnology Equity Research Team with Addition of Two Senior Analysts, Rick Bienkowski, Ph.D. and Caroline Palomeque

NEW YORK--(BUSINESS WIRE)--Ladenburg Thalmann & Co. Inc. (“Ladenburg Thalmann”), a middle-market investment bank providing investment banking, equity research, and institutional sales and trading services, and subsidiary of Osaic, Inc. (“Osaic”), today announced that Rick Bienkowski, Ph.D. and Caroline Palomeque have joined the firm’s Biotechnology Equity Research team as Managing Directors.

Dr. Bienkowski and Ms. Palomeque further expand Ladenburg Thalmann’s biotechnology equity research platform, enhancing coverage across gene therapy, genetic medicines, and innovative life sciences companies. Their addition reflects the firm’s continued investment in its research capabilities and commitment to providing fundamental research and industry analysis to institutional investors.

“We are excited to welcome Rick and Caroline to Ladenburg Thalmann,” said Michael Gideon, Co-Chief Executive Officer at Ladenburg Thalmann. “They each bring significant experience in biotechnology equity research, combining scientific expertise with deep fundamental analysis. Their addition expands our sector expertise and enhances our research coverage for institutional clients.”

“Rick and Caroline add meaningful depth to our biotechnology research platform,” said Jeffrey Cohen, Director of Research at Ladenburg Thalmann. “Both bring extensive experience covering innovative biotechnology companies and will play an important role in expanding our coverage within the sector.”

Dr. Bienkowski was Director of Biotechnology Equity Research at Cantor Fitzgerald, where he covered gene editing, cell therapy, and genetic medicine companies. He also held roles at SVB Leerink and RBC Capital Markets. Dr. Bienkowski holds a Ph.D. in Genetics and Molecular Biology from Emory University and a B.S. from Cornell University.

Prior to joining Ladenburg Thalmann, Ms. Palomeque was an Equity Research Analyst at Berenberg Capital Markets. In previous roles, she covered biotechnology companies at Maxim Group and WallachBeth and was a member of the biotechnology teams at Oppenheimer, JMP Securities, and Goldman Sachs. Ms. Palomeque holds an MBA in Finance from Fordham Graduate School of Business and a B.S. in Neuroscience from the University of Massachusetts Amherst.

Dr. Bienkowski and Ms. Palomeque will be based in Ladenburg Thalmann’s New York City office.

For more information, please visit ladenburg.com.

About Ladenburg Thalmann:

Ladenburg Thalmann & Co. Inc. is a full-service, diversified financial services firm that offers a range of investment banking and capital markets products and services, including equity and debt capital raising, mergers and acquisitions, corporate finance advisory, and fairness opinions. Ladenburg was established in 1876 and has been a member of the New York Stock Exchange since 1879.

About Osaic

Osaic, Inc. (“Osaic”), a portfolio company of Reverence Capital Partners, is one of the nation’s largest providers of wealth management strategies, supporting over 10,000 financial professionals. Osaic’s mission is to empower entrepreneurial advisors to create leading wealth management solutions that enhance lives and legacies. Visit www.osaic.com to learn more.

Securities and investment advisory services are offered through the firms: Osaic Wealth, Inc. and Osaic Institutions, Inc., broker-dealers, registered investment advisers, and members of FINRA and SIPC. Securities are offered through Osaic Services, Inc. and Ladenburg Thalmann & Co., broker-dealers and members of FINRA and SIPC. Advisory services are offered through Ladenburg Thalmann Asset Management, Inc., Osaic Advisory Services, LLC, and CW Advisors, LLC, registered investment advisers. Advisory programs offered by Osaic Wealth, Inc. are sponsored by VISION2020 Wealth Management Corp., an affiliated registered investment adviser.